A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

Khyatiben Rana,1 Jessica Reid,1 Joshua N Rosenwasser,2 Todd Lewis,3 Mae Sheikh-Ali,4 Rushab R Choksi,1 Rebecca F Goldfaden1 1East Coast Institute for Research, Jacksonville, FL, USA; 2Lincoln Medical and Mental Health Center, Bronx, NY, USA; 3Baker-Gilmour Cardiovascular Institute, Jacksonville, FL,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rana K, Reid J, Rosenwasser JN, Lewis T, Sheikh-Ali M, Choksi RR, Goldfaden RF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Praluent Alirocumab PCSK9 PCSK9-inhibitor Cardiovascular Disease Atherosclerosis Dyslipidemia Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/a2387d7fe44e466b93a14ba37ad96e96
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a2387d7fe44e466b93a14ba37ad96e96
record_format	dspace
spelling	oai:doaj.org-article:a2387d7fe44e466b93a14ba37ad96e962021-12-02T01:56:25ZA spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data1178-7007https://doaj.org/article/a2387d7fe44e466b93a14ba37ad96e962019-09-01T00:00:00Zhttps://www.dovepress.com/a-spotlight-on-alirocumab-in-high-cardiovascular-risk-patients-with-ty-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Khyatiben Rana,1 Jessica Reid,1 Joshua N Rosenwasser,2 Todd Lewis,3 Mae Sheikh-Ali,4 Rushab R Choksi,1 Rebecca F Goldfaden1 1East Coast Institute for Research, Jacksonville, FL, USA; 2Lincoln Medical and Mental Health Center, Bronx, NY, USA; 3Baker-Gilmour Cardiovascular Institute, Jacksonville, FL, USA; 4Northeast Florida Endocrine and Diabetes Associates, Jacksonville, FL, USACorrespondence: Rebecca F GoldfadenEast Coast Institute for Research, Jacksonville, FL, USATel +1 904 854 1354Fax +1 904 854 1355Email Rebecca.Goldfaden@ecirmed.comAbstract: Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of <70 mg/dL or target non-high-density lipoprotein goal of <100 mg/dL. Lipid-lowering therapies (LLTs), such as statins and ezetimibe, are the cornerstone for plasma LDL-C lowering; however, individuals with diabetes are often unable to achieve target lipid goals with these therapies alone and frequently require additional treatments. A new class of LLTs, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, provides a novel approach to lowering lipids in persons with high CV risk, such as those with diabetes. The clinical data presented in this review indicate the potential benefits of alirocumab in patients with diabetes and its value as a treatment option in patients with diabetic dyslipidemia with no significant safety concerns.Keywords: praluent, alirocumab, PCSK9, PCSK9 inhibitor, cardiovascular disease, atherosclerosis, dyslipidemiaRana KReid JRosenwasser JNLewis TSheikh-Ali MChoksi RRGoldfaden RFDove Medical PressarticlePraluentAlirocumabPCSK9PCSK9-inhibitorCardiovascular DiseaseAtherosclerosisDyslipidemiaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 1897-1911 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Praluent Alirocumab PCSK9 PCSK9-inhibitor Cardiovascular Disease Atherosclerosis Dyslipidemia Specialties of internal medicine RC581-951
spellingShingle	Praluent Alirocumab PCSK9 PCSK9-inhibitor Cardiovascular Disease Atherosclerosis Dyslipidemia Specialties of internal medicine RC581-951 Rana K Reid J Rosenwasser JN Lewis T Sheikh-Ali M Choksi RR Goldfaden RF A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
description	Khyatiben Rana,1 Jessica Reid,1 Joshua N Rosenwasser,2 Todd Lewis,3 Mae Sheikh-Ali,4 Rushab R Choksi,1 Rebecca F Goldfaden1 1East Coast Institute for Research, Jacksonville, FL, USA; 2Lincoln Medical and Mental Health Center, Bronx, NY, USA; 3Baker-Gilmour Cardiovascular Institute, Jacksonville, FL, USA; 4Northeast Florida Endocrine and Diabetes Associates, Jacksonville, FL, USACorrespondence: Rebecca F GoldfadenEast Coast Institute for Research, Jacksonville, FL, USATel +1 904 854 1354Fax +1 904 854 1355Email Rebecca.Goldfaden@ecirmed.comAbstract: Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of <70 mg/dL or target non-high-density lipoprotein goal of <100 mg/dL. Lipid-lowering therapies (LLTs), such as statins and ezetimibe, are the cornerstone for plasma LDL-C lowering; however, individuals with diabetes are often unable to achieve target lipid goals with these therapies alone and frequently require additional treatments. A new class of LLTs, proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, provides a novel approach to lowering lipids in persons with high CV risk, such as those with diabetes. The clinical data presented in this review indicate the potential benefits of alirocumab in patients with diabetes and its value as a treatment option in patients with diabetic dyslipidemia with no significant safety concerns.Keywords: praluent, alirocumab, PCSK9, PCSK9 inhibitor, cardiovascular disease, atherosclerosis, dyslipidemia
format	article
author	Rana K Reid J Rosenwasser JN Lewis T Sheikh-Ali M Choksi RR Goldfaden RF
author_facet	Rana K Reid J Rosenwasser JN Lewis T Sheikh-Ali M Choksi RR Goldfaden RF
author_sort	Rana K
title	A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
title_short	A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
title_full	A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
title_fullStr	A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
title_full_unstemmed	A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
title_sort	spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/a2387d7fe44e466b93a14ba37ad96e96
work_keys_str_mv	AT ranak aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT reidj aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT rosenwasserjn aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT lewist aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT sheikhalim aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT choksirr aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT goldfadenrf aspotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT ranak spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT reidj spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT rosenwasserjn spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT lewist spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT sheikhalim spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT choksirr spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata AT goldfadenrf spotlightonalirocumabinhighcardiovascularriskpatientswithtype2diabetesandmixeddyslipidemiaareviewontheemergingdata
_version_	1718402793516040192

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data

Ejemplares similares